Core Viewpoint - The company Zhaoke Ophthalmology-B (06622) has had its application for the registration of atropine sulfate eye drops accepted by the Australian Therapeutic Goods Administration, aimed at treating myopia progression in children [1] Group 1: Application Details - The application for the 0.01% atropine sulfate eye drops (product code: NVK002) was officially acknowledged by the Therapeutic Goods Administration on January 5, 2026, and has passed the preliminary review stage [1] - The application is supported by results from the company's Phase III clinical trials [1] Group 2: Product Information - Atropine sulfate eye drops (NVK002) are an experimental new topical ophthalmic solution designed to control myopia progression in children and adolescents [1] - The product features a patented formulation that successfully addresses the instability of low-concentration atropine, with global intellectual property protection [1] - The eye drops are preservative-free and are expected to have a shelf life of over 24 months [1] Group 3: Market Position - According to Zhi Shi Consulting, NVK002 is currently one of the most advanced atropine candidates globally for treating myopia progression, targeting a broad patient demographic of children and adolescents aged 3 to 17 [1]
兆科眼科-B(06622)：澳洲THERAPEUTIC GOODS ADMINISTRATION（治疗用品管理局）受理评核硫酸阿托品滴眼液的注册申请